Our findings, together with those previous studies, suggest that ibrutinib may not be a good choice in unselected EGFR-mutant NSCLC, but hold the promise in a subgroup of patients with osimertinib resistance induced by IL-6. This evidence concerns the gene IL6 and non-small cell lung carcinoma.